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PVIEWPOINT AND COMMENTARY
Heart Failure Guidelines, Performance Measures,
and the Practice of Medicine
Mind the Gap
Jalal K. Ghali, MD,* Barry M. Massie, MD,† Douglas L. Mann, MD,‡ Michael W. Rich, MD‡
Detroit, Michigan; San Francisco, California; and St. Louis, Missouri
Guidelines have rather quickly assumed a central role in health care delivery in the U.S. They have become the
foundation on which performance measures are built and, therefore, a major player in assessing the quality of
care provided by individuals and institutions, the ramifications of which involve reputation, reimbursement, and
litigation. We are concerned, however, that in our enthusiasm for collectively endorsing these guidelines, we are
marginalizing the importance of physician judgment and inadvertently risking the conversion of guidelines into
“cookbooks.” We believe that this viewpoint, while unequivocally acknowledging the fundamental importance of
guidelines, simultaneously provides a critically important perspective on the potential for misuse of both guide-
lines and performance measures. Further, we hope that publication of this viewpoint will help temper enthusi-
asm for overzealous conversion of guidelines into performance measures, thereby restoring the vital role of phy-
sician judgment and insight into patient management. (J Am Coll Cardiol 2010;56:2077–80) © 2010 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.07.013v
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pn the past 3 decades, countless randomized trials, meta-
nalyses, and large observational studies have led to major
dvances in the care of patients with a diverse array of
edical disorders, including heart failure (HF). These
tudies have spawned the era of evidence-based medicine,
nd the development and dissemination of authoritative
uidelines designed to facilitate patient management under
wide range of clinical situations. Optimally, guideline
ecommendations are derived from the results of major
linical trials, but it is important to recognize that for a large
roportion of important clinical questions for which defin-
tive trials are not available, recommendations are based
rimarily on expert opinion, which frequently requires
odification as new information becomes available. None-
heless, guidelines are an authoritative resource for practic-
ng physicians, and they serve a vital role in minimizing
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ccepted July 27, 2010.ariations in care by encouraging the implementation of
vidence-based interventions while discouraging potentially
armful ones. Although they are meant to supplement
ather than replace clinical judgment, they have been widely
erceived and accepted, perhaps somewhat simplistically
nd rigidly, as defining appropriate and inappropriate med-
cal care.
Implementation of guidelines into routine clinical prac-
ice has often been suboptimal at best, and as a result of
hich, many patients, including those with HF, frequently
eceive substandard care (1). This observation has led to the
evelopment of performance measures for evaluating and
eporting quality of care at the level of the hospital and
ndividual practitioner (2,3), and to the design and testing of
ethodologies for improving quality of care through closer
dherence to established guidelines (4–7). Although perfor-
ance measures incorporate clinical reasoning in determin-
ng the appropriateness of an intervention, the value of
erformance measures as a means for improving clinical
utcomes remains unproven (8,9). More recently, in addi-
ion to public reporting (10,11), pay-for-performance initi-
tives have been implemented (with more on the way) that
eward institutions and physicians for providing “better”
are, as judged by adherence to specific performance metrics
11–13), and many institutions and programs have incorpo-
ated their performance results into promotional materials.
ndeed, an “industry” has evolved to certify and promote
rograms based on these measures. Thus, the development
f guidelines has provided a benchmark upon which per-
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built, and has clearly signaled a
new era in health care delivery.
Few would argue with the con-
ceptual underpinnings of evidence-
based medicine, practice guide-
lines, performance measures, or
even a restructuring of the reim-
bursement system to better align
payment with the quality of care
provided (rather than with vol-
ume, the principal driver of re-
imbursement under the current
system). However, it must be
ecognized that there are important limitations to the
xisting evidence base, practice guidelines derived from that
vidence base, performance measures synthesized from less-
han-perfect guidelines, and reimbursement strategies that
ely too heavily on adherence to performance measures.
ndeed, overzealous application of guidelines, fueled in part
y vigorous promotion by professional organizations and in
ome cases by industry (which often has its own financial
ncentives for promoting guidelines that encourage use of
heir products), as well as by provider incentives to achieve
igher-quality ratings and, perhaps, higher reimbursement,
ay potentially have effects that are directly opposite to
hose intended. Thus, by diminishing the importance of
hysician judgment in managing the individual patient,
hereby fostering “cookbook medicine,” specific interven-
ions may be applied in patients who are unlikely to benefit
r who are potentially at risk for harm (14).
Considering the central role of guidelines, it is critical to
xamine the evidence base for the HF guidelines and define
heir limitations. A recent analysis of the distribution of
evels of evidence for recommendations in American Col-
ege of Cardiology/American Heart Association (ACC/
HA) clinical practice guidelines (15) found that for the
F guidelines, Level of Evidence: A (multiple clinical trials
nd/or meta-analyses) accounted for 26.4% of recommen-
ations, Level of Evidence: B (a single randomized trial or
onrandomized studies) for 19.4%, and Level of Evidence: C
expert opinion and observational studies) for 54.3%. Sim-
larly, the 2009 focused update of the ACC/AHA guide-
ines for the diagnosis and management of patients with HF
16) contains a total of 157 discrete recommendations, of
hich only 35 (22%) are supported by Level of Evidence: A.
nother 31 recommendations (20%) are based on Level of
vidence: B, whereas the majority, 91 (58%), are based
rimarily on expert consensus opinion.
Recommendations with the highest level of evidence are
ased on randomized clinical trials (RCTs) and are there-
ore subject to all the limitations of RCTs, which are
enerally performed in environments and patient popula-
ions that differ greatly from those of usual clinical practice.
his inherent selection bias of RCTs results in under-
Abbreviations
and Acronyms
ACC/AHA  American
College of Cardiology/
American Heart Association
ACEI  angiotensin-
converting enzyme inhibitor
HF  heart failure
ICD  implantable
cardioverter-defibrillator
RCT  randomized clinical
trialepresentation of the elderly, women, and minorities; con- persely, patients who are likely to be adherent to the
rescribed treatment and follow-up are over-represented
17). Comparing patients in RCTs to those in the commu-
ity reveals remarkable differences, including younger age
mean age 64 years vs. 73 years), under-representation of
omen (23% vs. 50%), and markedly limited ethnic/racial
iversity (18). Furthermore, trial patients tend to be health-
er, with fewer concomitant comorbidities, such as renal
nsufficiency, chronic lung disease, obesity, depression, and
eurocognitive disorders. These factors may significantly
mpact prognosis and the risk–benefit ratio of specific
herapies, in many cases more profoundly than the primary
llness. Thus, it is never safe to assume that treatments of
roven efficacy in younger, healthier, predominantly male,
nd white patients will provide equivalent benefit in older
atients, women, or ethnically diverse populations. For
xample, in a meta-analysis of the angiotensin-converting
nzyme inhibitor (ACEI) trials, Flather et al. (19) reported
hat among 1,066 patients over 75 years of age, ACEIs had
o discernible effect on mortality. More recently, in a
eta-analysis of 5 trials, Ghanbari et al. (20) reported that
mplantable cardioverter-defibrillators (ICDs) provided no
ortality benefit in women. Despite these studies, current
uidelines rarely distinguish use of these therapies on the
asis of age, sex, or concomitant conditions.
Concerns about the importance of race/ethnicity and the
otential for harm are exemplified by the use of aldosterone
ntagonists. Current ACC/AHA guidelines recommend
he use of an aldosterone antagonist in “selected patients
ith moderately severe to severe symptoms of HF and
educed left ventricular ejection fraction who can be care-
ully monitored for preserved renal function and normal
otassium concentration” (Level of Evidence: B) (16). This
ecommendation is based on 2 randomized trials, both of
hich enrolled carefully selected patients, with few subjects
ver 75 years of age, a minority of women, and very few
frican-Americans (21,22). Yet, the guidelines do not
xclude these subgroups from the recommendation to ini-
iate aldosterone antagonist therapy or emphasize the need
or caution in subgroups for which experience is limited.
his is noteworthy, since a recently published analysis from
he A-HeFT (African-American Heart Failure Trial) found
hat aldosterone antagonists were not associated with a
urvival benefit in African-American patients who were not
eceiving hydralazine and nitrates (23).
A further concern is that patients treated with an aldo-
terone antagonist in the context of a well-designed trial
eceived rigorous follow-up to monitor for adverse effects,
nd it cannot be expected that such meticulous follow-up
ould be matched in clinical practice. This is a particularly
mportant issue, since post-discharge follow-up of HF
atients is often inadequate (24). Indeed, the lack of
dequate caution in patient selection and assurance of
igorous follow-up is the likely explanation for the striking
ise in hyperkalemia and excess early mortality following
ublication of the RALES (Randomized Aldactone Evalu-
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tudy conducted in Canada in a “real-world” HF population
mean age 78 years, 50% women) (25). Moreover, spirono-
actone was not associated with reductions in either all-
ause mortality or HF admissions in this analysis.
These concerns notwithstanding, a recent analysis from
he AHA-sponsored Get With The Guidelines program
eported marked underutilization of aldosterone antagonists
n patients hospitalized with acute decompensated HF, and
he authors concluded that “stronger uptake of aldosterone
ntagonist therapy. . .may be warranted” (26). Notably, the
alue of spironolactone in patients hospitalized with decom-
ensated HF, who often have fluctuating renal function and
lectrolyte levels, has not been tested, and the potential for
arm induced by widespread initiation of spironolactone in
hese patients may be substantial. Furthermore, patients
ospitalized with HF represent a heterogeneous group,
ncluding some patients who experience substantial clinical
mprovement following hospital discharge, as a result of
hich, they may no longer fulfill guideline criteria for
ldosterone antagonist therapy and other interventions.
Another recommendation that raises concern in the
ranslation of guidelines into performance measures is the
se of ICDs. At present, there is no evidence from clinical
rials that ICDs reduce mortality in patients 80 years of age
r older (27,28), nor as noted previously, is there convincing
vidence of benefit in women (20). Yet, current guideline
ecommendations do not distinguish indications for ICD
nsertion based on age or sex (16). Thus, a 98-year-old
oman with Class III HF symptoms and a left ventricular
jection fraction of 28% should be considered for an ICD
Level of Evidence: A!) in the absence of contraindications.
oreover, the physician who fails to offer an ICD to such
patient risks being labeled as practicing “bad medicine,”
ith potentially serious ramifications for his or her practice
nd reimbursement.
A further concern is the subjectivity inherent in guideline
ecommendations based on consensus opinion of experts. A
ase in point is the addition of an angiotensin-receptor
locker in patients with reduced ejection fraction who
emain symptomatic despite treatment with ACEIs and
eta-blockers. Four separate guideline committees, upon
eviewing and analyzing the same data, have provided
ifferent recommendations and assigned different levels of
vidence, ranging from Class I, Level of Evidence: A to
lass II, Level of Evidence: B (Table 1) (16,29–31).
In summary, evidence-based medicine, practice guide-
ines, quality assurance programs, and performance mea-
ures unequivocally represent major advances towards en-
uring that the largest number of patients receives the
ighest quality of care. However, they also create the
otential for a “slippery slope” by inadvertently marginaliz-
ng the importance of physician judgment in providing truly
atient-centered care. The current enthusiasm for translat-
ng practice guidelines into routine clinical care needs to be
empered by a better understanding of the limitations of theuidelines and by an appreciation for the variable quality of
are and patient adherence that impact early outcomes as
atients transition from hospital to outpatient care.
Moreover, we believe that the push to convert guidelines
nto an ever-growing number of performance measures with
mplications for reimbursement should be undertaken with
greater degree of circumspection. As we move from
ractice guidelines to performance measures, it will be
mportant to “mind the gap” between what we truly know,
hat we think we know, and what we would like to know,
nd between the rigor of patient selection and follow-up in
CTs and the much more variable management that occurs
n clinical practice, lest we engage in more harm than good.
n this context, it must be recognized that guidelines are
erely guidelines, and that optimal patient care still requires
healthy dose of physician judgment.
eprint requests and correspondence: Dr. Jalal K. Ghali, DMC
ardiovascular Institute, 3990 John R. Street, Suite 9370, Wayne
tate University, Detroit, Michigan 48201. E-mail: JGhali@dmc.org.
EFERENCES
1. Stafford RS, Radley DC. The underutilization of cardiac medications
of proven benefit, 1990 to 2002. J Am Coll Cardiol 2003;41:56–61.
2. Specifications Manual for National Hospital Quality Measures Version
2.4: Measure Information Forms—Heart Failure (HF) (11/30/07). Joint
Commission on Accreditation of Healthcare Organizations (JCAHO).
Available at: http://www.jcaho.org/pms/coremeasures/aligned_
manual.htm. Accessed May 7, 2010.
3. Bonow RO, Bennett S, Casey DE Jr., et al. ACC/AHA clinical
performance measures for adults with chronic heart failure. J Am Coll
Cardiol 2005;46:1144–78.
4. Ansari M, Shlipak MG, Heidenreich PA, et al. Improving guideline
adherence: a randomized trial evaluating strategies to increase beta-
blocker use in heart failure. Circulation 2003;107:2799–804.
5. Fonarow GC, Abraham WT, Albert NM, et al. Organized program to
initiate lifesaving treatment in hospitalized patients with heart failure
(OPTIMIZE-HF): rationale and design. Am Heart J 2004;148:
43–51.
6. Fonarow GC, Yancy CW, Albert NM, et al. Improving the use of
evidence-based heart failure therapies in the outpatient setting: the
IMPROVE HF performance improvement registry. Am Heart J
2007;154:12–38.
7. Matthews JC, Johnson ML, Koelling TM. The impact of patient-
ecommendations for the Addition of ARBs inympto atic Patients With Syst lic HF ReceivingCEIs and Be a-Blockers
Table 1
Recommendations f r the Addition of ARBs in
Symptomatic Patients With Systolic HF Receiving
ACEIs and Beta-Blockers
Level of Evidence Class
CCS A I
HFSA A IIa
ACC/AHA B IIb
ESC
Cardiovascular death B IIa
HF hospitalization A I
CC/AHA  American College of Cardiology/American Heart Association; ACEI  angiotensin-
onverting enzyme inhibitor; ARB angiotensin receptor blocker; CCS Canadian Cardiovascular
ociety; ESC  European Society of Cardiology; HF  heart failure; HFSA  Heart Failure Society
f America.specific quality-of-care report cards on guideline adherence in heart
failure. Am Heart J 2007;154:1174–83.
11
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
3
2080 Ghali et al. JACC Vol. 56, No. 25, 2010
Guidelines and Performance Measures December 14/21, 2010:2077–808. Maeda JLK. Evidence-based heart failure performance measures and
clinical outcomes: a systematic review. J Cardiac Fail 2010;16:411–8.
9. Mazimba S, Grant N, Makola D, et al. Congestive heart failure
performance measures: does adherence impact early unplanned hospi-
tal readmissions (abstr)? J Am Coll Cardiol 2010;55 Suppl A:A139.
0. Marshall MN, Shekelle PG, Leatherman S, Brook RH. The public
release of performance data: what do we expect to gain? A review of the
evidence. JAMA 2000;283:1866–74.
1. Lindenauer PK, Remus D, Roman S, et al. Public reporting and pay
for performance in hospital quality improvement. N Engl J Med
2007;356:486–96.
2. Havranek DP, Krumholz HM, Dudley RA, et al. Aligning quality and
payment for heart failure care: defining the challenges. J Card Failure
2003;9:251–4.
3. Epstein AM, Lee TH, Hamel MB. Paying physicians for high-quality
care. N Engl J Med 2004;350:406–10.
4. Woolf SH, Grol R, Hutchinson A, Eccles M, Grimshaw J. Potential
benefits, limitations, and harms of clinical guidelines. BMJ 1999;318:
527–30.
5. Tricoci P, Allen JM, Kramer JM, et al. Scientific evidence underlying
the ACC/AHA clinical practice guidelines. JAMA 2009;301:831–41.
6. Jessup M, Abraham WT, Casey DE, et al. 2009 focused update
incorporated into the ACC/AHA guidelines for the evaluation and
management of heart failure in adults. J Am Coll Cardiol 2009;53:
e1–90.
7. Heiat A, Gross CP, Krumholz HM. Representation of the elderly,
women, and minorities in heart failure clinical trials. Arch Intern Med
2002;162:1682–8.
8. Ghali JK. The COHERE Registry: hype or hope? J Cardiac Fail
2000;6:272–5.
9. Flather MD, Yusuf S, Kober L, et al. Long-term ACE-inhibitor
therapy in patients with heart failure or left-ventricular dysfunction: a
systematic overview of data from individual patients. Lancet 2000;355:
1575–81.
0. Ghanbari H, Dalloul G, Hasan R, et al. Effectiveness of implantable
cardioverter-defibrillators for the primary prevention of sudden cardiac
death in women with advanced heart failure: a meta-analysis of
randomized controlled trials. Arch Intern Med 2009;169:1500–6. K1. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on
morbidity and mortality in patients with severe heart failure. Random-
ized Aldactone Evaluation Study Investigators. N Engl J Med 1999;
341:709–17.
2. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone
blocker, in patients with left ventricular dysfunction after myocardial
infarction. N Engl J Med 2003;348:1309–21.
3. Ghali JK, Tam SW, Sabolinski ML, et al. Exploring the potential
synergistic action of spironolactone on nitric oxide-enhancing therapy:
insights from the African American Heart Failure Trial. J Card Fail
2008;14:718–23.
4. Hernandez AF, Greiner MA, Fonarow GC, et al. Relationship
between early physician follow-up and 30-day readmission among
Medicare beneficiaries hospitalized for heart failure. JAMA 2010;303:
1716–22.
5. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia
after publication of the Randomized Aldactone Evaluation Study.
N Engl J Med 2004;351:543–51.
6. Albert NM, Yancy CW, Liang Li, et al. Use of aldosterone antagonists
in heart failure. JAMA 2009;302:1658–65.
7. Swindle JP, Rich MW, McGann P, Burroughs TE, Hauptman PJ.
Implantable cardiac device procedures in older patients. Use and
in-hospital outcomes. Arch Intern Med 2010;170:631–7.
8. Havranek EP, Peterson PN. Are implanted defibrillators effective
therapy in the elderly? Asked, not answered. Circ Heart Fail 2010;
3:4–6.
9. Arnold JM, Howlett JG, Ducharme A, et al. Canadian Cardiovascular
Society consensus conference guidelines on heart failure: 2008 update:
best practices for transition of care of heart failure patients, and the
recognition, investigation and treatment of cardiomyopathies. Can
J Cardiol 2008;24:21–40.
0. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for
the diagnosis and treatment of acute and chronic heart failure in 2008.
Eur J Heart Fail 2008;29:2388–442.
1. Adams KF, Lindenfeld J, Arnold JM, et al. HFSA 2006 comprehen-
sive heart failure practice guideline. J Card Fail 2006:12:e1–122.ey Words: guidelines y performance measures y practice of medicine.
